ifosfamide / Generic mfg.  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

10 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ifosfamide / Generic mfg.
NCT06236789: Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate Cancer

Recruiting
N/A
60
RoW
Ifosfamide/mesna
Yonsei University
Prostatic Neoplasm
11/26
11/26
NCT03360760: Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and Sacrum

Recruiting
N/A
100
RoW
Doxorubicin, Adriamycin, Cisplatin, cisplatinum, platamin, Methotrexate, HD-MTX, Ifosfamide, ifosphamide, definitive surgery, pre surgical chemotherapy, neoadjuvant chemotherapy
Peking University People's Hospital
Osteosarcoma of Pelvis
02/20
02/25
ChiCTR1900024967: Amroitinib hydrochloride combined with AI (doxorubicin + ifosfamide) for the treatment of high-grade soft tissue sarcomas with difficult surgical resection: a prospective, single arm, multi-center clinical study

Recruiting
N/A
78
 
Amroitinib hydrochloride
Beijing Jishuitan Hospital; Xijing Hospital, Military Medical University of The Air Force; Beijing Jishuitan Hospital, CHIATAI TIANQING
soft tissue sarcoma
 
 
NCT01464606: International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry

Active, not recruiting
N/A
156
US
Vincristine, Vincristine; Oncovin, Dactinomycin, Actinomycin-D, Cyclophosphamide, Cytoxan, Ifosfamide, Ifos, Doxorubicin, Adriamycin
Children's Hospitals and Clinics of Minnesota
Pleuropulmonary Blastoma
12/25
12/28
ChiCTR2100053594: Efficacy and safety of eribulin monotherapy or combination therapy in Chinese adults with soft tissue sarcoma

Not yet recruiting
N/A
 
Anthracycline-based drugs ;Ifosfamide-based ;Other chemotherapy options ;Combined molecular targeted therapy ;Combination immune checkpoint inhibitor therapy
Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, self-funded
soft tissue sarcoma (STS)
 
 
ChiCTR2000028961: Combination of high-throughput sequencing and primary cell culture as an exploratory study of individualized treatment of malignant tumors: phase 2 clinical trial of sintilimab for retroperitoneal dedifferentiation of liposarcoma

Not yet recruiting
N/A
30
 
Neoadjuvant sintilimab monotherapy ;Neoadjuvant sintilimab combined with epirubicin and/or ifosfamide
Department of Urology, Shanghai Changhai Hospital, the Second Military Medical University, Shanghai, China; Second Military Medical University, Innovent Biologics, Inc.
retroperitoneal dedifferentiated liposarcoma
 
 
NCT01505569: Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

Completed
N/A
44
US
Ifosfamide, Mitoxana, Ifex, Etoposide, Eposin, Etopophos, Vepesid, VP-16, Mesna, Uromitexan, Mesnex, G-CSF, Granulocyte colony-stimulating factor, Busulfan, Busulfex, Melphalan, 50 mg/m2 IV over 30 min, Thiotepa, Thioplex, Autologous stem cell infusion, Radiation, Carboplatin, Paraplatin, Paclitaxel, Taxol, Onxal, Leukapheresis, Anti-seizure prophylaxis, Ursodiol
Masonic Cancer Center, University of Minnesota
Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
02/24
02/24
NCT06451302: Risk Stratification Oriented Treatment of Pediatric Ewing Sarcoma: a Prospective Multicenter Cohort Study

Active, not recruiting
N/A
100
RoW
cyclophosphamide, adriamycin, vincristine，Ifosfamide，etoposide, vinorelbine
Yizhuo Zhang
Ewing Sarcoma, Risk Stratification
05/27
12/27
NCT06302465: Narlumosbartmab Combined With Neoadjuvant Chemotherapy in Bone-derived Malignancies With Osteolytic Lesions and Multinucleated Giant Cells

Recruiting
N/A
60
RoW
narlumosbartmab plus doxorubicin、cisplatin、methotrexate、ifosfamide, doxorubicin、cisplatin、methotrexate、ifosfamide
Peking University People's Hospital
Malignant Bone Tumor
11/26
12/26
ChiCTR2100051933: A non-randomized controlled, open, multi-center clinical study to compare doxorubicin hydrochloride liposome injection versus doxorubicin in the treatment of osteosarcoma

Not yet recruiting
N/A
200
 
Methotrexate+Ifosfamide+Doxorubicin Hydrochloride Liposome Injection+Cisplatin ;Methotrexate+Ifosfamide+Doxorubicin Hydrochloride+Cisplatin
Beijing Jishuitan Hospital; Beijing Jishuitan Hospital, CSPC Ouyi Pharmaceutical Co., Ltd.
osteosarcoma
 
 

Download Options